Panitumumab

Panitumumab (INN), formerly ABX-EGF, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1 and HER1 in humans). Panitumumab is manufactured by Amgen and marketed as Vectibix. It was originally developed by Abgenix Inc. In 2014, Amgen and Illumina entered into an agreement to develop a companion diagnostic to accompany panitumumab.[1] Contents 1 Medical uses 2 Contraindications 3 Adverse effects 4 Phar... [wikipedia]